Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VTRS Viatris Inc.

盘前交易 11-19 08:22:53 EST

13.00

+0.17

+1.33%

盘前12.97

-0.03-0.23%

08:10 EST

最高13.06	最低12.68	成交量902.52万
今开12.78	昨收12.83	日振幅2.96%
总市值155.17亿	流通市值154.30亿	总股本11.94亿
成交额1.17亿	换手率0.76%	流通股本11.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"VTRS","market":"US","secType":"STK","nameCN":"Viatris Inc.","latestPrice":13,"timestamp":1731963600000,"preClose":12.83,"halted":0,"volume":9025205,"hourTrading":{"tag":"盘前","latestPrice":12.97,"preClose":13,"latestTime":"08:10 EST","volume":155,"amount":2004.33011,"timestamp":1732021808003},"delay":0,"floatShares":1186953302,"shares":1193592902,"eps":-0.739178,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.17,"latestTime":"11-19 08:22:53 EST","open":12.78,"high":13.06,"low":12.68,"amount":116632534.68569499,"amplitude":0.029618,"askPrice":12.99,"askSize":400,"bidPrice":12.81,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.739178,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732026600000},"adr":0,"listingDate":1605157200000,"adjPreClose":13,"dividendRate":0.036923,"preHourTrading":{"tag":"盘前","latestPrice":12.97,"preClose":13,"latestTime":"08:10 EST","volume":155,"amount":2004.33011,"timestamp":1732021808003},"postHourTrading":{"tag":"盘后","latestPrice":13,"preClose":13,"latestTime":"19:13 EST","volume":473425,"amount":6154502.979,"timestamp":1731975191130},"volumeRatio":1.0683559699789897,"impliedVol":0.2459,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/VTRS","defaultTab":"news","newsList":[{"id":"2484102005","title":"晖致2024财年第三财季实现净利润94.80百万美元，同比减少71.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484102005","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484102005?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:01","pubTimestamp":1731772898,"startTime":"0","endTime":"0","summary":"11月17日，晖致公布财报，公告显示公司2024财年第三财季净利润为94.80百万美元，同比减少71.45%；其中营业收入为37.57亿美元，同比减少4.30%，每股基本收益为0.08美元。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000235abc78f6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000235abc78f6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"gpt_icon":0},{"id":"2481136077","title":"Viatris 公司报告截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2481136077","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481136077?lang=zh_cn&edition=full","pubTime":"2024-11-08 01:22","pubTimestamp":1731000131,"startTime":"0","endTime":"0","summary":"Viatris 公司报告截至 9 月 30 日的季度业绩 - 收益摘要Viatris Inc VTRS.OQ 公布的截至 9 月 30 日的季度调整后每股收益为 75 美分，低于去年同期的每股收益 79 美分。华尔街预期为每股收益 64 美分至 71 美分。营收同比下降 4.8%，至 37.5 亿美元；分析师预期为 37.1 亿美元。Viatris Inc 公布的本季度每股收益为 8 美分。公司报告的季度净收入为 9,480 万美元。本季度迄今为止，Viatris Inc 的股价保持稳定，今年迄今为止上涨了 7.2%。华尔街对 Viatris Inc 的 12 个月目标价中位数为 12.17 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4T3ME2H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4583","BK4588","LU1839511570.USD","VTRS","LU2087621335.USD","BK4585"],"gpt_icon":0},{"id":"2481181093","title":"BUZZ-第三季度业绩超出预期，Viatris 将迎来两年来业绩最好的一天","url":"https://stock-news.laohu8.com/highlight/detail?id=2481181093","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481181093?lang=zh_cn&edition=full","pubTime":"2024-11-07 23:05","pubTimestamp":1730991944,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    11月7日 - ** 制药商Viatris   股价上涨9%至12.65美元的三个月高点 ** 如果涨势得以保持，该股将迎来两年来最好的一天** 根据LSEG汇编的数据，伟哥生产商第三季度 (link)，营收37.4亿美元，超出华尔街预期的37.1亿美元。** 第三季度每股收益为75美分，高于预期的68美分。** 年初至今，股价上涨 16.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LU1839511570.USD","LU2087621335.USD","BK4583","VTRS","BK4007"],"gpt_icon":0},{"id":"2481095181","title":"BUZZ-第三季度业绩超出预期，Viatris 将迎来两年来业绩最好的一天","url":"https://stock-news.laohu8.com/highlight/detail?id=2481095181","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481095181?lang=zh_cn&edition=full","pubTime":"2024-11-07 23:05","pubTimestamp":1730991944,"startTime":"0","endTime":"0","summary":"** 第三季度每股收益为75美分，高于预期的68美分。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4T3ME23I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","VTRS","LU1839511570.USD","LU2087621335.USD","BK4588","BK4583"],"gpt_icon":0},{"id":"1142747545","title":"异动解读 | 新药亮眼业绩超预期 Viatris股价大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142747545","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142747545?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:48","pubTimestamp":1730990923,"startTime":"0","endTime":"0","summary":"制药公司Viatris股价在11月7日盘中大涨5.08%,引发市场关注。公司新鲜出炉的第三季度财报成为推动股价上涨的主因。数据显示,Viatris第三季度营收达37.4亿美元,超过分析师预期的37.1亿美元。Viatris是2020年由默克和辉瑞旗下业务合并组建而成,在品牌药和仿制药两大领域都有版图。除了新产品销售亮眼,公司传统品牌药如伟哥、Xanax等也保持了稳健增长。本季度,其品牌药业务同比增长2%至23.6亿美元,仿制药业务增长4%至13.8亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 新药亮眼业绩超预期 Viatris股价大涨5%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"gpt_icon":0},{"id":"2481890071","title":"晖致盘中异动 早盘快速上涨5.00%报12.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481890071","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481890071?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:33","pubTimestamp":1730990034,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日22时33分，晖致股票出现异动，股价快速拉升5.00%。截至发稿，该股报12.19美元/股，成交量53.4534万股，换手率0.04%，振幅3.88%。晖致股票所在的制药行业中，整体涨幅为0.63%。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110722335498e4131a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110722335498e4131a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1839511570.USD","VTRS","BK4583","LU2087621335.USD","BK4007","BK4585","BK4588"],"gpt_icon":0},{"id":"2481790016","title":"新仿制药需求旺盛，安乃近制造商 Viatris 季度业绩超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2481790016","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481790016?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:52","pubTimestamp":1730987529,"startTime":"0","endTime":"0","summary":"Viatris 的产品组合包括勃起功能障碍药物伟哥、抗焦虑药物 Xanax、癫痫治疗药物 Lyrica 和关节炎治疗药物 Celebrex 等主要品牌药物。Viatris 于 6 月份完成了对妇女健康和活性药物成分   业务的剥离。根据 LSEG 编制的数据，这家制药商第三季度的收入为 37.4 亿美元，超过了 分析师平均预期的 37.1 亿美元。调整后的季度利润为每股 75 美分，也高于预期的 68 美分。不过，Viatris 将 2024 年的利润预期从之前的每股 2.58 美元至 2.73 美元下调至 2.56 美元至 2.71 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","API","LU0321505439.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","LU0456855351.SGD","LU0170899867.USD","IE00B19Z3B42.SGD","BK4592","BK4568","SG9999002224.SGD","VTRS","BK4023","BK4535","BK4007","BK4581","BK4503","BK4533","LU1839511570.USD","SG9999013999.USD","LU0058720904.USD","LU0289739699.SGD","BK4585","LU0234572021.USD","LU0306807586.USD","SG9999001176.USD","LU1066053197.SGD","IE00BLSP4452.SGD","SG9999002232.USD","LU2087621335.USD","LU0122379950.USD","BK4551","LU0868494617.USD","SG9999011175.SGD","IE00BLSP4239.USD","BK4550","BK4534","SGXZ57979304.SGD","LU0306806265.USD","IE0002270589.USD","LU0985481810.HKD","LU1894683348.USD","BK4583","LU1066051498.USD","LU0225771236.USD","LU1023059063.AUD","SG9999001176.SGD","IE00B19Z3581.USD","BK4588"],"gpt_icon":1},{"id":"2481001999","title":"新仿制药需求旺盛，安乃近制造商 Viatris 季度业绩超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2481001999","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481001999?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:52","pubTimestamp":1730987529,"startTime":"0","endTime":"0","summary":"新仿制药需求旺盛，安乃近制造商 Viatris 季度业绩超出预期路透11月7日 - 制药商维特瑞VTRS.O周四公布的第三季度利润和营收超出华尔街预期，这主要得益于其哮喘和多动症等新仿制药的强劲需求，该公司股价盘前上涨了2.5%。Viatris 于 6 月份完成了对妇女健康和活性药物成分   业务的剥离。不过，Viatris 将 2024 年的利润预期从之前的每股 2.58 美元至 2.73 美元下调至 2.56 美元至 2.71 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4T3ME1N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0957799991.USD","LU1894683348.USD","LU1066053197.SGD","BK4533","IE00B2B36J28.USD","LU0784385840.USD","LU1894683264.USD","LXRX","LU0058720904.USD","LU0225771236.USD","BK4585","AZN.UK","LU0077335932.USD","LU0792757196.USD","LU1839511570.USD","LU0203345920.USD","SG9999003800.SGD","BK4588","LU0882574055.USD","LU0047473722.EUR","LU0868494617.USD","LU0963555726.SGD","BK4534","LU0985481810.HKD","03165","VTRS","LU0976567544.SGD","BK5011","LU0997586432.USD","LU0114720955.EUR","PFE","LU0203347892.USD","LU0456855351.SGD","LU0889565080.SGD","LU0949170426.SGD","IE00BLSP4239.USD","LU0170899867.USD","IE0002141913.USD","BK4581","LU0310799852.SGD","LU0553294199.USD","LU0225284248.USD","LU0211327993.USD","LU0823416689.USD","LU0661504455.SGD","SG9999002224.SGD","SG9999002232.USD","BK4568","SG9999001176.USD","LU0011850046.USD"],"gpt_icon":1},{"id":"2474826278","title":"BUZZ-Viatris 的焦虑症药物在后期试验中达到主要目标；股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2474826278","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474826278?lang=zh_cn&edition=full","pubTime":"2024-10-09 23:42","pubTimestamp":1728488555,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透10月9日 - **制药商Viatris   股价上涨1%，报11.44美元 ** 该公司的药物Effexor (link) 在治疗日本成年患者广泛性焦虑症的后期研究中达到了主要和次要目标(GAD) ** 研究显示，在治疗焦虑症 8 周时，艾菲克索的疗效优于安慰剂** 艾菲克索的耐受性总体良好，与已知的非日本患者的安全状况一致** 该公司计划于 2025 年向日本监管机构提交艾菲克索的申请** 艾菲克索在 80 多个国家被批准用于治疗 GAD** 包括本交易日的走势在内，该股今年累计上涨 5.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","VTRS","BK4583","BK4588","LU2087621335.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2472579443","title":"吉利德与 6 家仿制药生产商签署协议，在低收入国家销售艾滋病药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2472579443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472579443?lang=zh_cn&edition=full","pubTime":"2024-10-03 00:52","pubTimestamp":1727887935,"startTime":"0","endTime":"0","summary":"    路透10月2日 - 吉利德科学公司  周三表示，该公司已向六家仿制药生产商授予了免版税许可，允许它们在120个低收入和中低收入国家生产和销售更廉价的仿制版艾滋病预防药物。这些国家约占艾滋病病例的 70%。该制药商表示，它将在今年年底前开始申请全球监管机构批准该药物作为预防艾滋病的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU0058720904.USD","BK4007","BK4568","LU1066051498.USD","BK4585","LU0109394709.USD","LU0889565916.HKD","BK4583","BK4550","IE00BZ1G4Q59.USD","BK4578","LU2087621335.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LU2468319806.SGD","LU1571399168.USD","BK4139","LU1585245621.USD","IE00BSNM7G36.USD","LU0234570918.USD","VTRS","IE00B19Z3581.USD","BK4532","GILD","IE0002270589.USD","LU1839511570.USD","BK4566","LU1066053197.SGD","BK4588"],"gpt_icon":0},{"id":"2468621448","title":"晖致盘中异动 早盘急速下跌5.00%报11.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468621448","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468621448?lang=zh_cn&edition=full","pubTime":"2024-09-20 22:11","pubTimestamp":1726841500,"startTime":"0","endTime":"0","summary":"北京时间2024年09月20日22时11分，晖致股票出现异动，股价快速下跌5.00%。截至发稿，该股报11.31美元/股，成交量237.805万股，换手率0.20%，振幅3.78%。晖致股票所在的制药行业中，整体涨幅为1.26%。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092022114198e38448&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092022114198e38448&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","VTRS","BK4007","BK4588","LU2087621335.USD","LU1839511570.USD","BK4583"],"gpt_icon":0},{"id":"2464832025","title":"美国允许增加武田多动症药物的产量以解决短缺问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2464832025","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464832025?lang=zh_cn&edition=full","pubTime":"2024-09-04 18:57","pubTimestamp":1725447431,"startTime":"0","endTime":"0","summary":"    路透9月4日 - 美国缉毒署 已将武田制药  的多动症药物Vyvanse及其仿制药的生产限额提高了约24%，以解决该药在美国持续短缺的问题。美国食品和药物管理局在2022年10月警告 ，以色列制药商Teva Pharmaceutical Industries的  Adderall因生产延误而出现短缺。这导致需求激增，武田的Vyvanse随之出现短缺。Vyvanse又名利眠宁，被美国缉毒署列为第二类管制药物，适用于被认为极有可能被滥用的药物，并规定了额外的处方保障措施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VTRS","BK4007","BK4583","LU2087621335.USD","LU1839511570.USD","BK4585","ADHD"],"gpt_icon":0},{"id":"2464202563","title":"美国允许增加武田多动症药物的产量以解决短缺问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2464202563","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464202563?lang=zh_cn&edition=full","pubTime":"2024-09-04 18:57","pubTimestamp":1725447431,"startTime":"0","endTime":"0","summary":"    路透9月4日 - 美国缉毒署 已将武田制药  的多动症药物Vyvanse及其仿制药的生产限额提高了约24%，以解决该药在美国持续短缺的问题。美国食品和药物管理局在2022年10月警告 ，以色列制药商Teva Pharmaceutical Industries的  Adderall因生产延误而出现短缺。这导致需求激增，武田的Vyvanse随之出现短缺。Vyvanse又名利眠宁，被美国缉毒署列为第二类管制药物，适用于被认为极有可能被滥用的药物，并规定了额外的处方保障措施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","VTRS","BK4583","LU2087621335.USD","BK4007","BK4585","BK4588","ADHD"],"gpt_icon":0},{"id":"2460736913","title":"晖致2024财年第二财季实现净利润-3.26亿美元，同比减少223.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460736913","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460736913?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:02","pubTimestamp":1723910554,"startTime":"0","endTime":"0","summary":"8月18日，晖致公布财报，公告显示公司2024财年第二财季净利润为-3.26亿美元，同比减少223.48%；其中营业收入为37.87亿美元，同比减少3.17%，每股基本收益为-0.27美元。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180004139f340506&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180004139f340506&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"gpt_icon":0},{"id":"1189672840","title":"异动解读 | Viatris Inc.第二季度业绩超预期 股价大涨11.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189672840","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189672840?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:09","pubTimestamp":1723190948,"startTime":"0","endTime":"0","summary":"8月8日,制药公司Viatris Inc.(VTRS)盘中股价大涨11.88%,报收于12.00美元/股。这主要得益于公司公布的第二季度业绩超出市场预期,以及对未来新产品销售前景的乐观预期。\n\n财报数据显示,Viatris第二季度每股收益为69美分,高于华尔街预期的68美分。营收达到38亿美元,也超过了预期的37.8亿美元。公司表示,第二季度品牌药和仿制药需求强劲,是业绩超预期的主要原因。\n\n与此同时,Viatris还上调了其新产品系列2024年销售额预期,从之前的4.5亿至5.5亿美元上调至5亿至6亿美元。这一预期调整反映了公司对新产品前景的信心,也为股价上涨增添了动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":0},{"id":"1103823632","title":"异动解读 | Viatris Inc.第二季度业绩超预期 股价盘中大涨6.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103823632","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103823632?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:05","pubTimestamp":1723190722,"startTime":"0","endTime":"0","summary":"制药公司Viatris Inc.周四盘中股价大涨6.25%,主要得益于公司公布的第二季度业绩超出市场预期。公司每股收益为69美分,也略高于分析师平均预期的68美分。作为伟哥和Xanax等知名药品的生产商,Viatris在非专利品牌药和仿制药领域具有领先地位。除了当季业绩表现亮眼外,Viatris还上调了对2024年新产品系列销售的预期。公司预计2024年新产品销售额将达到5亿至6亿美元,高于之前4.5亿至5.5亿美元的预期区间。这一乐观预期进一步增强了市场对Viatris长期增长前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":0},{"id":"1166152495","title":"异动解读 | Viatris公司品牌药和仿制药业务表现亮眼,股价盘前大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166152495","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166152495?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:04","pubTimestamp":1723190684,"startTime":"0","endTime":"0","summary":"制药公司Viatris Inc.今日盘前股价大涨5.28%,引发市场关注。这主要得益于公司第二季度财报表现优异,品牌药和仿制药业务需求强劲。\n\nViatris公司第二季度利润和收入均超出华尔街预期。公司品牌药和仿制药部门收入同比增长2%,成为业绩亮点。这家伟哥生产商的非专利品牌药和仿制药产品在市场上备受青睐。\n\n与此同时,Viatris公司正在进行业务重组,剥离非处方药、活性药物成分和女性健康业务,以专注于眼科、消化科和皮肤科三大核心领域。公司还上调了2024年新产品系列销售预期,反映出对未来增长的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":0},{"id":"2457319166","title":"晖致盘中异动 早盘快速上涨5.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457319166","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457319166?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:30","pubTimestamp":1723123827,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时30分，晖致股票出现异动，股价大幅上涨5.63%。截至发稿，该股报12.00美元/股，成交量5.6112万股，换手率0.00%，振幅0.00%。晖致股票所在的制药行业中，整体跌幅为1.03%。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808213027aefdefec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808213027aefdefec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2087621335.USD","BK4588","LU1839511570.USD","BK4585","VTRS","BK4007","BK4583"],"gpt_icon":0},{"id":"2457561316","title":"BUZZ--美国股票走势-Datadog、Palantir、NRG 能源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2457561316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457561316?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:29","pubTimestamp":1723123759,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      8月8日 - 美国股指期货周四涨跌不一，投资者在就业报告公布前转为谨慎，上周的经济数据弱于预期，引发了对经济衰退的担忧。美东时间9:10 ，道指电子盘  上涨0.34%，报39,036 点。标普500指数小型股  上涨0.89%，报5274.25点；纳斯达克100指数小型股  上涨1.20%，报18182.25点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WBD","BK4125","LU0345774631.USD","LU2326559502.SGD","UAA","BK4023","IE00B4R5TH58.HKD","SGXZ81514606.USD","SGXZ99366536.SGD","LU0456855351.SGD","BK4581","PGEN","BK4547","LU1023059063.AUD","BK4588","LU2286300806.USD","LU0417517546.SGD","LU0320765059.SGD","LU0198837287.USD","BK4139","LU0672654240.SGD","LU1064131342.USD","IE00B2B36J28.USD","LU0640476718.USD","BK4532","SEDG","GDRX","PLTR","LU0106261372.USD","LU1267930730.SGD","BK4543","DDOG","LU0256863902.USD","IE00BK4W5M84.HKD","BUZZ","LU0289739699.SGD","BMBL","NRG","BK4167","LU0345774391.USD","BK4504","IE00BK4W5L77.USD","MNST","LU0471298777.SGD","ALDX","VTRS","LU0238689110.USD"],"gpt_icon":1},{"id":"2457318237","title":"BUZZ-Viatris 因第二季度利润和销售额超出预期而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2457318237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457318237?lang=zh_cn&edition=full","pubTime":"2024-08-08 20:51","pubTimestamp":1723121482,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    8月8日 - ** 制药商Viatris   股价盘前上涨4.8%至11.90美元** 伟哥和Xanax生产商第二季度每股收益为69美分，高于 (link) 华尔街预期的68美分 - LSEG** 该公司第二季度营收为 38 亿美元，高于预期的 37.8 亿美元。** VTRS 将其新产品系列的 2024 年销售额预期上调至 5 亿至 6 亿美元，而之前的预期为 4.5 亿至 5.5 亿美元。** 截至最后收盘，股价累计上涨 4.9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","BK4585","LU1839511570.USD","BK4007","LU2087621335.USD","BK4588","VTRS","BK4583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viatris.com","stockEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":0.1054},{"period":"3month","weight":0.1149},{"period":"6month","weight":0.1954},{"period":"1year","weight":0.3757},{"period":"ytd","weight":0.2004}],"compareEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":0.0061},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.1101},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.2374}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viatris Inc.于2019年2月14日在特拉华州成立。该公司是一家全球性的医疗保健公司，该公司认为他们具有独特的定位，可以弥合仿制药和品牌之间的传统鸿沟，将两者的优点结合起来，以更全面地满足全球范围内的医疗保健需求。Viatris的使命是赋能世界各地的人们在生命的每个阶段都能过上更健康的生活，它大规模地提供准入服务，目前每年为全球约10亿患者提供高质量的药物，并触及生命的所有时刻，从出生到生命的尽头，从急性病到慢性病。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.048097},{"month":2,"riseRate":0.25,"avgChangeRate":-0.100502},{"month":3,"riseRate":0,"avgChangeRate":-0.065492},{"month":4,"riseRate":0,"avgChangeRate":-0.039911},{"month":5,"riseRate":0.5,"avgChangeRate":0.057634},{"month":6,"riseRate":0.5,"avgChangeRate":-0.028874},{"month":7,"riseRate":0.5,"avgChangeRate":0.024935},{"month":8,"riseRate":0.75,"avgChangeRate":0.011976},{"month":9,"riseRate":0,"avgChangeRate":-0.075843},{"month":10,"riseRate":0.25,"avgChangeRate":0.018996},{"month":11,"riseRate":0.75,"avgChangeRate":0.040773},{"month":12,"riseRate":1,"avgChangeRate":0.100515}],"exchange":"NASDAQ","name":"Viatris Inc.","nameEN":"Viatris Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viatris Inc.,VTRS,Viatris Inc.股票,Viatris Inc.股票老虎,Viatris Inc.股票老虎国际,Viatris Inc.行情,Viatris Inc.股票行情,Viatris Inc.股价,Viatris Inc.股市,Viatris Inc.股票价格,Viatris Inc.股票交易,Viatris Inc.股票购买,Viatris Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}